

Joshua Richter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2525869/publications.pdf>

Version: 2024-02-01

55
papers

1,358
citations

566801

15
h-index

360668

35
g-index

59
all docs

59
docs citations

59
times ranked

1827
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Oral Selinexor + Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738. | 13.9 | 460 |
| 2 | Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 859-866. | 0.8 | 140 |
| 3 | A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. <i>Journal of Hematology and Oncology</i> , 2020, 13, 94. | 6.9 | 107 |
| 4 | Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 10. | 2.8 | 53 |
| 5 | Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. <i>Science Advances</i> , 2021, 7, eabg9551. | 4.7 | 49 |
| 6 | COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. <i>Blood Cancer Discovery</i> , 2020, 1, 234-243. | 2.6 | 46 |
| 7 | Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 2616. | 2.2 | 44 |
| 8 | Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. <i>Lancet Haematology</i> , 2022, 9, e143-e161. | 2.2 | 44 |
| 9 | Bispecific Antibodies in Multiple Myeloma: Present and Future. <i>Blood Cancer Discovery</i> , 2021, 2, 423-433. | 2.6 | 43 |
| 10 | Bispecifics, trispecifics, and other novel immune treatments in myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 264-271. | 0.9 | 40 |
| 11 | Selinexor in relapsed/refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072093062. | 1.1 | 35 |
| 12 | Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 632-636.e1. | 0.2 | 31 |
| 13 | B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198958. | 1.1 | 24 |
| 14 | Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. <i>Blood</i> , 2018, 132, 598-598. | 0.6 | 17 |
| 15 | Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. <i>Expert Review of Hematology</i> , 2020, 13, 943-958. | 1.0 | 16 |
| 16 | Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e470-e476. | 0.2 | 12 |
| 17 | Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date. <i>Seminars in Oncology</i> , 2020, 47, 155-164. | 0.8 | 11 |
| 18 | POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 297-304. | 0.2 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072098707. | 1.1 | 10 |
| 20 | Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 752-765. | 0.2 | 10 |
| 21 | Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. <i>Expert Review of Hematology</i> , 2021, 14, 1099-1114. | 1.0 | 10 |
| 22 | Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. <i>Frontiers in Oncology</i> , 2021, 11, 819127. | 1.3 | 10 |
| 23 | Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e284-e289. | 0.2 | 9 |
| 24 | Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. <i>Cancer</i> , 2021, 127, 1816-1826. | 2.0 | 9 |
| 25 | Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 1658-1658. | 0.6 | 9 |
| 26 | Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 407-414. | 0.2 | 8 |
| 27 | Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021, 21, 993. | 1.1 | 8 |
| 28 | Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab. <i>Blood</i> , 2020, 136, 6-7. | 0.6 | 8 |
| 29 | A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2208-2215. | 0.6 | 7 |
| 30 | A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2021, 14, 31-45. | 1.0 | 7 |
| 31 | A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. <i>JCO Precision Oncology</i> , 2022, , . | 1.5 | 7 |
| 32 | What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. <i>Targeted Oncology</i> , 2022, 17, 383-405. | 1.7 | 7 |
| 33 | E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients. <i>Blood</i> , 2018, 132, 3216-3216. | 0.6 | 6 |
| 34 | Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T. <i>Blood</i> , 2021, 138, 2704-2704. | 0.6 | 6 |
| 35 | Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 693-702. | 0.2 | 5 |
| 36 | Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, E430-E433. | 2.0 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma. <i>Blood</i> , 2018, 132, 59-59. | 0.6 | 4 |
| 38 | The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , . | 0.2 | 3 |
| 39 | Walking on myeloma. <i>Blood</i> , 2018, 132, 1724-1724. | 0.6 | 2 |
| 40 | A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1881-1891. | 1.3 | 2 |
| 41 | Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 100, 3057-3060. | 0.8 | 2 |
| 42 | Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e734-e751. | 0.2 | 2 |
| 43 | Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e341-e344. | 0.2 | 2 |
| 44 | Anti-body building: The exercise of advancing immune based myeloma therapies. <i>Blood Reviews</i> , 2021, 48, 100789. | 2.8 | 2 |
| 45 | Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522199553. | 0.5 | 1 |
| 46 | Management of patients with difficult-to-treat multiple myeloma. <i>Future Oncology</i> , 2021, 17, 2089-2105. | 1.1 | 1 |
| 47 | Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 129-132. | 0.2 | 1 |
| 48 | Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance. <i>Blood</i> , 2019, 134, 1779-1779. | 0.6 | 1 |
| 49 | Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature. <i>Blood</i> , 2021, 138, 457-457. | 0.6 | 1 |
| 50 | Are 4-Drug Regimens Here to Stay? Role in Induction and Salvage Therapies. <i>Cancer Journal (Sudbury,)</i> Tj ETQq0 0 0 rgBT /Ovrlock 10 T | 1.9 | 0 |
| 51 | Recapturing disease response: A phase 2 study of carfilzomib 56â€‰%mg/m² in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27â€‰%mg/m². <i>American Journal of Hematology</i> , 2020, 95, E51-E54. | 2.0 | 0 |
| 52 | Real-World Multiple Myeloma Treatment Patterns By Patient Characteristics and Outcomes in the United States. <i>Blood</i> , 2021, 138, 4114-4114. | 0.6 | 0 |
| 53 | Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease. <i>Blood</i> , 2021, 138, 3759-3759. | 0.6 | 0 |
| 54 | Characteristics of a Comprehensive, Continuously Updated Longitudinal Database for Multiple Myeloma. <i>Blood</i> , 2021, 138, 4969-4969. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Variation in the Treatment of Multiple Myeloma in the Real World. Blood, 2020, 136, 43-44. | 0.6 | 0 |